sponsored
PatientsVille.com Logo

PatientsVille

Gonadorelin Medical Research Studies

Up-to-date List of Gonadorelin Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Gonadorelin Medical Research Studies

Rank Status Study
1 Unknown  Comparing Coasting by Withholding GnRH Agonist With GnRH Antagonist
Condition: In Vitro Fertilization
Interventions: Procedure: GnRH antagonist;   Procedure: withdrawing GnRH agonists
Outcome Measures: decreased levels of estradiol (E2);   The days of coasting;   number of oocytes retrieved;   pregnancy rate;   the incidencess of OHSS
2 Recruiting GnRH Antagonist Versus GnRH Agonist in Polycystic Ovary Syndrome During in Vitro Fertilization - Embryo Transfer
Conditions: Infertility;   Polycystic Ovary Syndrome
Interventions: Drug: GnRH antagonist (Cetrorelix);   Drug: Conventional GnRH agonist (Triptorelin)
Outcome Measures: number of oocyte retrieved;   pregnancy rate
3 Recruiting LutrePulse Hypogonadotropic Hypogonadism
Condition: Primary Amenorrhea With Hypogonadotropic Hypogonadism
Interventions: Drug: Gonadorelin acetate 10µg/pulse;   Drug: Gonadorelin acetate 20µg/pulse;   Drug: Placebo
Outcome Measures: Ovulation rate;   Proportion of subjects with presence of gestational sac and fetal heart movement on transvaginal ultrasound after a second positive serum pregnancy test;   Proportion of subjects with a confirmed positive serum pregnancy test after luteinizing hormone (LH) surge;   Number of follicles with a mean diameter ≥14 mm;   Number of dominant follicles with a mean diameter of ≥ 18mm;   Maximum progesterone levels;   Mean progesterone levels;   Change from baseline in follicle-stimulating hormone (FSH) and LH;   Mean serum FSH and LH levels;   Estradiol serum levels;   Proportion of subjects with at least 1 post-baseline progesterone level ≥ 10 ng/mL
4 Recruiting Long Acting FSH Plus Antagonist Versus Daily FSH Plus Antagonist Versus Short Agonist Protocol in Poor Responders Undergoing IVF
Conditions: Female Infertility;   Poor Responder
Interventions: Drug: Long acting FSH and GnRH antagonist;   Drug: Daily FSH and GnRH antagonist;   Drug: Triptorelin and recombinant FSH
Outcome Measures: Clinical pregnancy rate;   Implantation rate
5 Recruiting Studying the Effects of 7 Days of Gonadotropin Releasing Hormone (GnRH) Treatment in Men With Hypogonadism
Conditions: Kallmann Syndrome;   Idiopathic Hypogonadotropic Hypogonadism;   GnRH Deficiency
Intervention: Drug: gonadotropin releasing hormone (GnRH)
Outcome Measures: testosterone;   LH;   FSH;   Inhibin B;   free alpha subunit
6 Unknown  Agonist Gonadotropin-Releasing Hormone (GnRH) Versus Antagonist GnRH
Condition: Infertility
Interventions: Drug: ganirelix;   Drug: suprefact
Outcome Measures: pregnancy rate;   ovarian stimulation
7 Recruiting Oestradiol Pre-treatment in an Ultrashort Flare GnRH Agonist/GnRH Antagonist Protocol in Poor Responders Undergoing IVF
Condition: Infertility
Interventions: Procedure: Oestradiol pre-treatment and combination of GnRH agonist/antagonist protocol;   Procedure: GnRH agonist or antagonist protocol without oestradiol pre-treatment
Outcome Measures: Live birth rate;   Clinical pregnancy rate;   Number of oocytes retrieved;   Top embryo quality at day 2;   Biochemical pregnancy;   Ectopic pregnancy;   Miscarriage rate
8 Not yet recruiting Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)
Condition: Prostate Cancer
Interventions: Drug: abiraterone acetate + prednisone + LHRH-therapy;   Drug: abiraterone acetate + prednisone
Outcome Measures: radiographic-progression-free survival;   Correlation of radiographic-progression-free survival with early PSA-response;   Hormonal analyses;   Adverse Events
9 Unknown  Evaluation of the Luteolytic Effect of a Gonadotropin Releasing Hormone (GnRH) Agonist After the Administration of Human Chorionic Gonadotropin (hCG) in the Initial Follicular Phase a Its Influence on the Prognosis of in Vitro Fertilization Treatment
Condition: Infertility
Interventions: Drug: GnRH agonist;   Drug: Control
Outcome Measures: Frequency of functional rescue of corpus luteum;   Pregnancy rate;   Levels of serum steroids;   Levels of serum gonadotropins
10 Recruiting Long Acting LHRH Versus Short Acting LHRH in the Treatment of Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: luteinizing hormone-releasing hormone (LHRH) short acting or long acting
Outcome Measures: The primary objective of this study is the median time to testosterone recovery in patients receiving 6 X 1-month or 2 X 3-month LHrH preparations and TPIP as radical treatment for limited stage prostate cancer.;   In this context, testosterone recovery is defined as the return to the lower limit of normal for the patient's age group as well as return to pre treatment levels.;   PSA profile, quality of life, sexual function
11 Recruiting Pulsatile GnRH in Anovulatory Infertility
Conditions: Hypogonadotropic Hypogonadism;   Amenorrhea;   Kallmann's Syndrome
Interventions: Drug: synthetic gonadotropin releasing hormone (GnRH);   Device: Mini-infusion pump
Outcome Measure: presence of ovulation and/or pregnancy
12 Not yet recruiting LH Response to GnRH Test in Prepubescent Girls Under 6 Years
Condition: Precocious Puberty
Intervention: Drug: GnRH agonist
Outcome Measures: LH response;   FSH response
13 Recruiting A Prospective, Randomised, Multi-centre Phase II Study Evaluating the Adjuvant, Neoadjuvant or Palliative Treatmant With Tamoxifen +/- GnRH Analogue Versus Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients
Condition: Male Breast Cancer
Interventions: Drug: Tamoxifen;   Drug: Tamoxifen and GnRH analogue;   Drug: Exemestane and GnRH analogue
Outcome Measures: Estradiol blood concentation;   Estradiol blood concentration;   Compliance;   Efficacy;   Efficacy perameters;   Safety and side effect parameters
14 Recruiting Luteal Supplementation With GnRH-agonist After GnRH-agonist Triggering in Combination With Low Dose HCG in IVF
Condition: Infertility
Interventions: Drug: Triptorelin 0.1mg;   Drug: Placebo 1 ml Nacl 0.9% solution
Outcome Measures: implantation rate;   chemical pregnancy;   clinical pregnancy;   live birth
15 Not yet recruiting Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank Donation
Condition: Egg Donation
Interventions: Drug: Follistim;   Drug: Ganirelix;   Drug: Menotropins;   Drug: Leuprolide;   Procedure: Transvaginal ultrasound guided needle aspiration of oocytes
Outcome Measures: number of mature oocytes recovered and cryopreserved.;   1) #Days of ovarian stimulation to GnRH agonist trigger.;   2) Peak serum estradiol level on day of GnRH agonist trigger;   Number of follicles >15 mm average diameter on day of GnRH agonist trigger
16 Recruiting Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS)
Conditions: Kallmann Syndrome;   Hypogonadotropic Hypogonadism;   GnRH Deficiency
Intervention: Drug: gonadotropin releasing hormone (GnRH)
Outcome Measures: endogenous LH secretion pattern;   testicular volume;   sperm count
17 Not yet recruiting LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: enzalutamide;   Drug: bicalutamide;   Procedure: orchiectomy;   Drug: leuprolide acetate;   Drug: goserelin acetate;   Other: laboratory biomarker analysis
Outcome Measures: Achievement of PSA remission assessed using the Prostate Cancer Clinical Trials Working Group (PCWG2) criteria;   Achievement of measurable disease assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1;   Achievement of PSA response assessed using PCWG2 criteria;   Duration of RD;   Duration of SDD;   TTF;   TTP;   TTP in patients with bone metastases;   PFS;   OS;   Occurrence rate of toxicity, graded per the Common Terminology Criteria for Adverse Events 4.0;   Occurrence rate of SRE;   Distribution of time until SRE;   Occurrence rate of CTC response
18 Recruiting Evaluation of Granulosa Cells Function After IVF Protocols
Conditions: Infertility;   In Vitro Fertilization Protocols
Intervention: Drug: randomization between the two GnRH analogues (agonist and antagonist)
Outcome Measures: Evaluation of steroid secretion and enzyme expression in in vitro luteinized granulosa cells;   Number of retrieved oocytes;   number of embryos;   Subgroup analyses comparing FSH versus HMG protocols
19 Unknown  Comparing Ovarian Stimulation for Assisted Reproduction With Two Different Forms of Pituitary Suppression
Conditions: Female Infertility Due to Nonimplantation of Ovum;   Complications Associated With Artificial Fertilization
Interventions: Drug: Pergoveris in long protocol with GnRH agonist;   Drug: Pergoveris in GnRH antagonist protocol
Outcome Measures: number of mature oocytes;   incidence of ovarian hyperstimulation syndrome (OHSS);   The number of early miscarriages.;   The number of participants with adverse events.
20 Recruiting AMH Levels Change During Treatment With GnRh Agonist
Conditions: Uterine Fibroids;   Endometriosis;   Endometriosis of Uterus;   Pelvic Pain
Intervention: Drug: GnRH analogue
Outcome Measures: AMH levels change before and after GnRHa;   Preantral and antral follicles;   Correlation between AMH levels and preantral and antral follicles count

These studies may lead to new treatments and are adding insight into Gonadorelin etiology and treatment.

A major focus of Gonadorelin research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Gonadorelin